Newsletters

Imagion Chats with 180 Markets on the Future of Cancer Detection
Catch Imagion’s CEO, Bob Proulx, chat with 180 Markets CEO, Greg Lowe, about the future of cancer detection and how our MagSense® medical imaging
Cleansing Notice – Entitlement Offer Shares
This notice is given by Imagion Biosystems Limited (the ‘Company’ or ‘IBX’) under section 708AA(2)(f) of the Corporations Act 2001 (Cth) (‘Corporations Act’) as modified
Non-renounceable Entitlement Offer
MELBOURNE – Imagion Biosystems (ASX:IBX, Imagion or the Company), a company dedicated to improving healthcare through the early detection of cancer, today advises that it
Imagion Funding Update
Highlights: Shareholder entitlement offer seeking to raise up to $2.4 million Funding facility of up to $15 million secured with Mercer Street Global Opportunity Fund,
Imagion Secures Growth Funding
Highlights: Imagion secures a funding facility of up to $15 million to support next phase of clinical and oncology pipeline development Funding Facility includes: $1.5 million
Imagion Receives 2nd CSIRO Federal Government Grant for Prostate Cancer Project
MELBOURNE — Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of cancer, is pleased to announce that it
Imagion Biosystems 2022 Annual Report
Imagion Biosystems has released its Annual Report for the year ending 31 December 2022. [See linked documents below] 2022 Research & Development Highlights: March 2022
Biotech Daily — Dr Boreham’s Crucible: Imagion Biosystems
Tim Boreham has taken another look at Imagion Biosystems in his latest “Dr. Boreham’s Crucible” column on Biotech Daily. In the column, Tim discusses the
Biotech Daily — Imagion Trial Review Backs Magsense for All Cancer MRI
“Imagion says it will prioritize development of its Magsense nanoparticle technology as imaging agents for mainstream clinical magnetic resonance imaging (MRI) scanners. Imagion said that
Positive independent review sets priority path to market for MagSense® Technology
https://www.youtube.com/watch?v=g8SnQWwJh68 Highlights Blinded review by panel of expert breast radiologists corroborates potential for MagSense® nanoparticle technology to detect tumour cells in lymph nodes by Magnetic
Quarterly Activity Report – Quarter Ending 31 December 2022
Highlights: Imagion presented results from MagSense® HER2 Phase I study at global breast cancer meeting showing safety and detectability Tasks expert panel of radiologists with
Quarterly Activity Report – Quarter Ending 30 September 2022
Highlights: Imagion presented prostate cancer research data at World Molecular Imaging Conference (WMIC) Receipt of $2.5 million R&D tax incentive (post-quarter end) MELBOURNE – Imagion
Imagion Biosystems receives AU$2.5 million in R&D tax incentives
ASX Announcement: MELBOURNE — Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of cancer, is pleased to report
Half-Year Results for the First Half of 2022 and Appendix 4D
Today, we released our Appendix 4D and Half-Year Financial Report for the half-year ending 30 June 2022 to the ASX. 1H2022 Highlights: MagSense® HER2 breast
Quarterly Activity Report and Appendix 4C for 30 June 2022
Imagion has released the Quarterly Activity Report and Appendix 4C for the period ending on 30 June 2022. The announcement highlights: MagSense® HER2 imaging agent
Q&A Session at 2022 Annual General Meeting
Imagion Biosystems recording of the Q&A session at the 2022 Annual General Meeting. Imagion Biosystems’ board of directors answer questions from shareholders at the AGM
Results of 2022 Annual General Meeting
In accordance with ASX Listing Rule 3.13.2 and section 251AA of the Corporations Act 2001, Imagion Biosystems Limited advises the results of its Annual General
Presentation Visuals from 25th May 2022 Annual General Meeting
The presentation visuals from the 25th May 2022 Annual General Meeting are now available. You can find the 2022 AGM Investor Presentation here. Other
Chairman’s Address to Shareholders at 2022 Annual General Meeting
Imagion Biosystems recording and transcript of the Chairman’s address to shareholders at the 2022 Annual General Meeting. Dear Shareholders, It is my pleasure to welcome
Quarterly Activity Report and Appendix 4C for 31 Mar 2022
Imagion has released the Quarterly Activity Report and Appendix 4C for the period ending on 31 March 2022. The announcement highlights: MagSense® HER2 breast cancer
Imagion Biosystems April 2022 Investor Newsletter
We are pleased to provide our investors with our April 2022 Investor Newsletter. In this edition, our Chief Financial Officer, Geoff Hollis, gives a recap
MagSense® HER2 Breast Cancer First-in-human Study Progress Update
Imagion Biosystems Limited (ASX: IBX) is pleased to provide an update on the progress of its first-in-human study for the MagSense® HER2 breast cancer imaging
Imagion Biosystems 2021 Full Year Results
Imagion Biosystems has released its Annual Report for the year ended 31 December 2021. See linked documents below. 2021 Clinical Highlights: Multiple patients enrolled and
Quarterly Activity Report and Appendix 4C for 31 December 2021
Imagion has released the Quarterly Activity Report and Appendix 4C for the period ending on 31 December 2021. The announcement highlights a recap of the
Transforming medical imaging for early disease detection
We’re on a mission to make cancer more detectable.